Clinical trials in Canada: Whose interests are paramount?

International Journal of Health Services

Volumn 38, Issue 3, 2008, Pages 525-542

  Lexchin, Joel ^a  

^a YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; GUIDELINE; HEALTH POLICY; PHARMACEUTICAL INDUSTRY; PUBLIC HEALTH;

CANADA; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG INDUSTRY; DRUG SCREENING; HEALTH CARE POLICY; PATIENT SELECTION; PRACTICE GUIDELINE; RESEARCH ETHICS; REVIEW;

CANADA; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DRUG APPROVAL; DRUG INDUSTRY; ETHICS, RESEARCH; HUMANS; PATIENT SELECTION; RESEARCH SUPPORT AS TOPIC;

EID: 57749176495     PISSN: 00207314     EISSN: 15414469     Source Type: Journal    
DOI: 10.2190/HS.38.3.h     Document Type: Review

References (62)

1. CBC Television. Marketplace: Drug Trials. March 18, 2003. www.cbc.ca/consumers/market/files/health/drug_trials (January 19, 2008).
2. Silversides, A. The tribulations of community-based trials. CMAJ 170:33, 2004.
3. Patented Medicine Prices Review Board. Annual Report 2001. Ottawa, 2002.
4. Patented Medicine Prices Review Board. Annual Report 2003. Ottawa, 2004.
5. Patented Medicine Prices Review Board. Annual Report 2005. Ottawa, 2006.
6. Health Products and Food Branch. Review of the 2001 Clinical Trials Regulatory Framework: Part C, Division 5 of the Food and Drug Regulations (Drugs for Clinical Trials Involving Human Subjects). Health Canada, Ottawa, 2007.
7. Health Canada. Background: Food and Drugs Act and Regulations. 2006. www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/clini/ cta_background_e.html (January 19, 2008).
8. Bégin, M., et al. Accelerating Access for Patients to Best Medicine: The System and the Challenge. Centre on Governance and Institute of Population Health, University of Ottawa, Ottawa, 2002.
9. Industry Canada. Canada-Your Innovation Partner in Clinical Trials (2006). 2007. http://strateigs.ic.gc.ca/epic/site/lsi-isv.nsf/en/li00255e.html (January 19, 2008).
10. Warda, J. Measuring the Attractiveness of R&D Tax Incentives: Canada and Major Industrial Countries. A report prepared for Foreign Affairs and International Trade Canada, Ontario Investment Service, and Statistics Canada. Statistics Canada, Ottawa, 1999.
11. Kermani, F., and Gittins, R. Canada Commits to R&D. 2004. www.inpharm.com/External/InpH/1,,1-3-0-0-inp_intelligencve_art-0-144037,00.html (January 19, 2008).
12. Government of Canada. Regulations amending the Food and Drug Regulations (1024-clinical trials): Regulatory impact analysis statement. Canada Gazette 134:227-260, 2000. http://canadagazette.gc.ca/partI/2000/20000122/ html/regle-e. html#i2 (January 19, 2008).
13. Karleff, I. Canada may speed access to its human guinea pigs: Ethicists queasy about plan to approve clinical trials in 48 hours. Globe and Mail (Toronto), October 25, 1999.
14. Government of Canada. Regulations amending the Food and Drug Regulations (1024 - clinical trials). Canada Gazette 135:1116-1153, 2001.
15. Auditor General of Canada. Allocating funds to regulatory programs - Health Canada. In Report of the Auditor General of Canada to the House of Commons, chap. 8. Ottawa, 2006.
16. Therapeutic Products Programme. International Strategy. Ottawa, April 1999.
17. Abraham, J., and Reed, T. Managing Knowledge and Expertise in Innovative Drug Testing. Economic and Social Research Council, Swindon, 1998.
18. Abraham, J., and Reed, T. Trading risks for markets: The international harmonisation of pharmaceuticals regulation. Health Risk Society 3:113-128, 2001.
19. Standing Senate Committee on Social Affairs Science and Technology. The Health of Canadians - The Federal Role, Vol. 5: Principles and Recommendations for Reform - Part 1. The Senate, Ottawa, 2002.
20. Department of Justice. Food and Drug Regulations. Ottawa, 2006. http://laws.justice.gc.ca/enF-27/C.R.C.-c.870/text.html (January 19, 2008).
21. Lemmens, T., and Miller, P. B. The human subjects trade: Ethical and legal issues surrounding recruitment incentives. J. Law Med. Ethics 31:398-418, 2003.
22. Beagan, B. L. Section E-1: Ethics review for human subjects research - interviews with members of research ethics boards and national organizations. In The Governance of Health Research Involving Human Subjects (HRIHS), ed. M. McDonald. Law Commission of Canada, 2000.
23. Munro, M. Doctors buying ethics approval. Vancouver Sun, February 27, 2004.
24. Lemmens, T., and Freedman, B. Ethics review for sale? Conflict of interest and commercial research review boards. Milbank Q. 78:547-584, 2000.
25. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Interagency Secretariat on Research Ethics, Ottawa, 2005.
26. Munro, M. UBC broke federal ethics rules by failing to adequately warn patients. Vancouver Sun, February 25, 2004.
27. Walters, J. Prozac research targets local girls. Hamilton Spectator, November 2, 2001.
28. Munro, M. Critical patients not informed UBC trial could hasten death: U.S. health officials. Vancouver Sun, February 27, 2004.
29. Munro, M. Doctors pressure human guinea pigs. Vancouver Sun, February 23, 2004.
30. Cornacchia, C. Cozying up to drug firms disturbs some physicians. Montreal Gazette, February 24, 2004.
31. Walker, R. Why FP research works. Medical Post, August 10, 1999, p. 31.
32. Munro, M. Drug firms pay $3,000 or more per patient for trials. Vancouver Sun, February 24, 2004.
33. Lippman, A. The Inclusion of Women in Clinical Trials: Are We Asking the Right Questions? Women and Health Protection, Toronto, 2006.
34. Rochon, P. A., Berger, P. B., and Gordon, M. The evolution of clinical trials: Inclusion and representation. CMAJ 159:1373-1374, 1998.
35. Caron, J. Report on Governmental Health Research Policies Promoting Gender or Sex Differences Sensitivity. Institute of Gender and Health, Ottawa, 2003.
36. Health Products and Food Branch. Guidance for Industry: Clinical Investigation of Medicinal Products in the Pediatric Population: ICH Topic E11. Health Canada, Ottawa, 2003.
37. Munro, M. "You failed to protect rights, safety and welfare" of boy. Vancouver Sun, February 26, 2004.
38. Canadian Press. Health Canada Sets New Clinical Drug Trial Rules. October 16, 2006. www.ctv.ca/servlet/ArticleNews/print/CTVNews/20061016/ h_canada_tr_061016/20061016/?hub=Health&subhub=PrintStory (January 19, 2008).
39. Health Canada. To Clinical Trial Sponsors: Requirements for Tuberculosis Screening of Healthy Volunteers in Phase I Clinical Trials Involving Immunosuppressant Drugs or Drugs with Immunosuppressant Properties. Ottawa, July 23, 2006.
40. Health Products and Food Branch. Summary Report of the Inspections of Clinical Trials Conducted in 2003/2004. Health Canada, Ottawa, 2004.
41. Kessler, D. A., et al. Therapeutic-class wars - drug promotion in a competitive marketplace. N. Engl. J. Med. 331:1350-1353, 1994.
42. Mirowski, P., and Van Horn, R. The contract research organization and the commercialization of scientific research. Soc. Stud. Sci. 35:503-548, 2005.
43. Rochon, P. A., et al. Reporting of gender-related information in clinical trials of drug therapy for myocardial infarction. CMAJ 159:321-327, 1998.
44. Mello, M. M., Clarridge, B. R., and Studdert, D. M. Academic medical centers' standards for clinical-trial agreements with industry. N. Engl. J. Med. 352:2202-2210, 2005.
45. Naylor, C. D., and Research Committee and Clinical Study Agreements Working Group of the Toronto Academic Health Science Council. Early Toronto experience with new standards for industry-sponsored clinical research - a progress report. CMAJ 166:453-456, 2002.
46. Lexchin, J., and Mintzes, B. Transparency in drug regulation: Mirage or oasis? CMAJ 171:1363-1365, 2004.
47. Health Canada. Issue Analysis Summary: Summary Basis of Decision - Draft 7. Ottawa, 2004.
48. Kondro, W., and Sibbald, B. Drug company experts advised staff to withhold data about SSRI use in children. CMAJ 170:783, 2004.
49. Mathews, A. W., and Martinez, B. Warning signs: e-mails suggest Merck knew Vioxx's dangers at early stage as heart-risk evidence rose, officials played hardball; internal message: "dodge!" Wall Street Journal, November 1, 2004.
50. Meier, B. Merck backs U.S. database to track drug trials. New York Times, June 18, 2004.
51. Zarin, D. A., Tse, T., and Ide, N. C. Trial registration at clinicaltrials.gov between May and October 2005. N. Engl. J. Med. 353:2779-2787, 2005.
52. Health Canada. Clinical Trials: Registration and Disclosure of Information. 2006. www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/proj/enreg-clini- info/2006-consult/index_e/html (January 19, 2008).
53. External Working Group on the Registration and Disclosure of Clinical Trial Information (EWG-CT). Final Report: Options for Improving Public Access to Information on Clinical Trials of Health Problems in Canada. Health Canada, Ottawa, 2006.
54. Health Canada: Drugs and Health Products. Clinical Trials: Registration and Disclosure of Information. 2007. www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/ proj/enreg-clini-info/2005-consult/index_e.html (January 19, 2008).
55. Lexchin, J. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: A hypothesis-generating study. Ann. Pharmacotherapy 40:2216-2222, 2006.
56. Lawson, G. W. Impact of User Fees (i.e. Drug Industry Fees) on Changes within the FDA. 2005. www.fdastudy.com (January 19, 2008).
57. Therapeutic Products Directorate. Business Transformation Progress Report. Health Canada, Ottawa, undated.
58. Government of Canada. The Canada We Want: Speech from the Throne to Open the Second Session of the Thirty-Seventh Parliament of Canada. Ottawa, 2003.
59. Graham, J. Smart regulation: Will the government's strategy work? CMAJ 173:1469-1470, 2005.
60. External Advisory Committee on Smart Regulation. Risk Management. Undated. http://epe.lac-bac.gc.ca/100/206/301/pco-bcp/committees/ smart_regulation-ef/2006-10-11/www.pco-bcp.gc.ca/smartreg-regint/en/index.html (January 19, 2008).
61. Health Canada. Health Protection Legislative Renewal: Detailed Legislative Proposal. Ottawa, 2003.
62. Hawthorne, F. Inside the FDA. John Wiley and Sons, Hoboken, NJ, 2005